Skip to main content
Erschienen in: Intensive Care Medicine 1/2006

01.01.2006 | Editorial

Statins: the next step in adjuvant therapy for sepsis?

verfasst von: Armand Mekontso-Dessap, Christian Brun-Buisson

Erschienen in: Intensive Care Medicine | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Excerpt

Statins are powerful hypolipemic drugs with pleiotropic effects and have been shown to improve survival in the primary and secondary prevention of atherosclerosis in numerous large randomized clinical trials [16]. Interestingly, in many of these trials, their beneficial clinical impact included noncoronary events. For example, statin therapy was consistently associated with decreased C-reactive protein (CRP) levels in recent human clinical trials, although the magnitude of this effect varied between drugs [7]. …
Literatur
1.
Zurück zum Zitat Kumana CR, Cheung BM, Lauder IJ (2003) Simvastatin reduced mortality and vascular events in high-risk patients. ACP J Club 138:2–3PubMed Kumana CR, Cheung BM, Lauder IJ (2003) Simvastatin reduced mortality and vascular events in high-risk patients. ACP J Club 138:2–3PubMed
2.
Zurück zum Zitat The Scandinavian Simvastatin Survival Study (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383–9PubMed The Scandinavian Simvastatin Survival Study (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383–9PubMed
3.
Zurück zum Zitat The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–57CrossRefPubMed The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–57CrossRefPubMed
4.
Zurück zum Zitat Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefPubMed Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefPubMed
5.
Zurück zum Zitat Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158CrossRefPubMed Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158CrossRefPubMed
6.
Zurück zum Zitat Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504CrossRefPubMed Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504CrossRefPubMed
7.
Zurück zum Zitat Chan KY, Boucher ES, Gandhi PJ, Silva MA (2004) HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61:1676–1681PubMed Chan KY, Boucher ES, Gandhi PJ, Silva MA (2004) HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61:1676–1681PubMed
8.
Zurück zum Zitat Arnaud C,Mach F (2005) Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98:661–666PubMed Arnaud C,Mach F (2005) Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98:661–666PubMed
9.
Zurück zum Zitat Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188–4194CrossRefPubMed Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188–4194CrossRefPubMed
10.
Zurück zum Zitat Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, Egido J (2003) Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57:168–177CrossRefPubMed Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, Egido J (2003) Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57:168–177CrossRefPubMed
11.
Zurück zum Zitat Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21:1327–1332PubMed Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21:1327–1332PubMed
12.
Zurück zum Zitat Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841–1846CrossRefPubMed Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841–1846CrossRefPubMed
13.
Zurück zum Zitat Krysiak R, Okopien B, Herman Z (2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63:1821–1854PubMed Krysiak R, Okopien B, Herman Z (2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63:1821–1854PubMed
14.
Zurück zum Zitat Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:575–585CrossRefPubMed Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:575–585CrossRefPubMed
15.
Zurück zum Zitat Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110:3349–3354CrossRefPubMed Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110:3349–3354CrossRefPubMed
16.
Zurück zum Zitat Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J (2004) Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21:271–275CrossRefPubMed Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J (2004) Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21:271–275CrossRefPubMed
17.
Zurück zum Zitat Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136:143–149PubMed Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136:143–149PubMed
18.
Zurück zum Zitat Landry DW,Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588–595CrossRefPubMed Landry DW,Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588–595CrossRefPubMed
19.
Zurück zum Zitat Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043–1046PubMed Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043–1046PubMed
20.
Zurück zum Zitat Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560–2565CrossRefPubMed Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560–2565CrossRefPubMed
21.
Zurück zum Zitat Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117–124CrossRefPubMed Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117–124CrossRefPubMed
22.
Zurück zum Zitat Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885CrossRefPubMed Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885CrossRefPubMed
23.
Zurück zum Zitat Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352–1357CrossRefPubMed Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352–1357CrossRefPubMed
24.
Zurück zum Zitat Fernandez R, De Pedro VJ, Artigas A (2005) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2005. DOI: 10.1007/s00134-005-2743-9 Fernandez R, De Pedro VJ, Artigas A (2005) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2005. DOI: 10.​1007/​s00134-005-2743-9
25.
Zurück zum Zitat Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2005) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2005. DOI: 10.1007/s00134-005-2859-y Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2005) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2005. DOI: 10.​1007/​s00134-005-2859-y
Metadaten
Titel
Statins: the next step in adjuvant therapy for sepsis?
verfasst von
Armand Mekontso-Dessap
Christian Brun-Buisson
Publikationsdatum
01.01.2006
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 1/2006
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-005-2860-5

Weitere Artikel der Ausgabe 1/2006

Intensive Care Medicine 1/2006 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.